Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.
IOL selection and power calculation present unique challenges in patients who previously had radial keratotomy. Due to the profound alterations in corneal shape and structural integrity induced by the incisions, target refraction is hard to achieve with traditional and premium IOLs, often leading to residual refractive errors, poor vision quality and overall dissatisfaction. Because RK procedures

At least 24.5% of former NFL players who died between 2016 and 2021 had chronic traumatic encephalopathy at death, according to research published in The BMJ.
Although researchers said they were not surprised by the direction of the findings, the magnitude was striking, said Daniel H. Daneshvar, MD, PhD, chair of the department of physical medicine and rehabilitation at Mass General Brigham.
The true prevalence of chronic traumatic encephalopathy (CTE) in the cohort of players is almost certainly higher than one-quarter, he said.
“We cannot say precisely how much higher from these data, but even

A 37-year-old man presented as a polytrauma after a motor vehicle accident with multiple injuries to the sternum, bilateral rib fractures, pneumothorax, pelvic fractures, left foot fractures and bilateral upper extremity fractures.
Review of left elbow radiographs showed a proximal transolecranon fracture with subsequent radial head dislocation. A CT scan of the left elbow was obtained, further characterizing a separate coronoid fragment not attached to either the olecranon nor the ulnar metaphysis, representing a transulnar basal coronoid fracture-dislocation.
Surgical fixation was recommended

The FDA added a boxed warning detailing the known risk for symptomatic hypophosphatemia associated with ferric carboxymaltose injection, according to an agency press release.
The boxed warning recommends phosphate monitoring for patients at risk for hypophosphatemia and any patients who receive a repeat course of therapy within 3 months of the prior course. Generic ferric carboxymaltose injection products are also expected to update their labels to reflect the added boxed warning, according to the release.
Ferric carboxymaltose injection (Injectafer, Daiichi Sankyo/American Regent), a

The internet went mainstream less than 40 years ago, yet it is hard to remember the world without it.
Chadi Nabhan, MD, MBA, hematologist, medical oncologist, podcaster and author, believes the same will hold true for AI in the not-so-distant future.
“There’s no way around it. AI is here to stay,” Nabhan told Healio. “Humans who are smart in using AI will advance better and faster in life and in career than humans who do not embrace AI.”
The same holds true in healthcare. Clinicians and institutions that best utilize AI will likely have the greatest impact on patients.
Barriers remain to

Novartis has halted eight trials of its cellular therapy rapcabtagene autoleucel in patients with rheumatic and neurological autoimmune disorders, due to three fatalities, according to reports.
The company implemented the pause on Aug. 24. The impacted trials included patients with lupus, rheumatoid arthritis, vasculitis, MS and myasthenia gravis.
A comprehensive review of the deaths is under way, Novartis told Reuters. The company said it is working with independent safety boards to review the events and determine the causes and associated factors.
Two trials of rapcabtagene autoleucel, also

In a crossover trial near Boston, adults 40 and older completed an executive function task 12 percent faster after a month using a HEPA purifier.

Rutgers researchers found waist circumference performed nearly as well as complex multi measurement frameworks at identifying unhealthy body fat.

In a 109 patient trial, omega 3 plus low dose aspirin matched antibiotics for severe gum disease, with 57.7 percent versus 58 percent hitting the goal.

Novartis says remibrutinib beat teriflunomide on relapse rates in two Phase 3 MS trials, but has not released the underlying numbers.